Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in postmenopausal osteoporosis: phase 3 results up to month 12

Langdahl, B., Chung, Y.-S., Plebanski, R. et al. (13 more authors) (2024) Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in postmenopausal osteoporosis: phase 3 results up to month 12. The Journal of Clinical Endocrinology & Metabolism. dgae611. ISSN 0021-972X

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.

Keywords: Clinical trials; Menopause; Metabolic bone disease; Osteoporosis
Dates:
  • Published: 7 September 2024
  • Published (online): 7 September 2024
  • Accepted: 5 September 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Depositing User: Symplectic Sheffield
Date Deposited: 15 Oct 2024 13:18
Last Modified: 15 Oct 2024 13:18
Status: Published online
Publisher: The Endocrine Society
Refereed: Yes
Identification Number: 10.1210/clinem/dgae611
Related URLs:
Open Archives Initiative ID (OAI ID):

Download

Export

Statistics